The effect of bevacizumab on colon anastomotic healing in rats

International Journal of Colorectal Disease

Volumn 25, Issue 12, 2010, Pages 1465-1473

  Pavlidis, Efstathios T ^a   Ballas, Konstantinos D ^a   Symeonidis, Nikolaos G ^a   Psarras, Kyriakos ^a   Koliakos, Georgios ^b   Kouzi Koliakos, Kokona ^b   Topouridou, Konstantina ^b   Rafailidis, Savas F ^a   Pavlidis, Theodoros E ^a   Marakis, Georgios N ^a   Sakantamis, Athanasios K ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Antiangiogenic agents; Avastin; Bevacizumab; Colorectal cancer targeted therapy; Experimental; Wound healing

Indexed keywords

BEVACIZUMAB; C REACTIVE PROTEIN; COLLAGEN; ENDOTHELIN 1; HYDROXYPROLINE; PLACEBO; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON ANASTOMOSIS; CONTROLLED STUDY; FIBROBLAST; FIBROSIS; INFLAMMATION; ISCHEMIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; RAT; SINGLE DRUG DOSE; WOUND HEALING;

ANASTOMOSIS, SURGICAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; COLON; COLORECTAL NEOPLASMS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTRAOPERATIVE CARE; ISCHEMIA; POSTOPERATIVE COMPLICATIONS; RATS; RATS, WISTAR; WOUND HEALING;

EID: 78149406727     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-010-1039-x     Document Type: Article

References (47)

1. RR McWilliams C Erlichman 2005 Novel therapeutics in colorectal cancer Dis Colon Rectum 48 1632 1650 10.1007/s10350-005-0026-8 15906130 (Pubitemid 41032091)
2. AD Thornton P Ravn M Winslet, et al. 2006 Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer Br J Surg 93 1456 1463 1:CAS:528:DC%2BD2sXlsF2mtA%3D%3D 10.1002/bjs.5624 17115389 (Pubitemid 44893645)
3. I Krämer HP Lipp 2007 Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer J Clin Pharm Ther 32 1 14 10.1111/j.1365-2710.2007.00800.x 17286784 (Pubitemid 46213936)
4. PL McCormack SJ Keam 2008 Bevacizumab: a review of its use in metastatic colorectal cancer Drugs 68 487 506 1:CAS:528:DC%2BD1cXmtFKlu74%3D 10.2165/00003495-200868040-00009 18318567 (Pubitemid 351342019)
5. I Kocakova I Kocak M Savoboda, et al. 2009 Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer Klin Onkol 22 73 76 1:STN:280:DC%2BD1MvhslygtA%3D%3D 19522377
6. SS Shord LR Bressler LA Tierney, et al. 2009 Understanding and managing the possible adverse effects associated with bevacizumab Am J Health Syst Pharm 66 999 1013 1:CAS:528:DC%2BD1MXnslWht7k%3D 10.2146/ajhp080455 19451611
7. B Gruenberger D Tamandl J Schueller, et al. 2008 Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer J Clin Oncol 26 1830 1835 1:CAS:528:DC%2BD1cXmsFemsbg%3D 10.1200/JCO.2007.13.7679 18398148
8. C Brostjan K Gebbardt B Gruenberger, et al. 2008 Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenetic balance is sensitive to systemic thrombospondin-1 levels Clin Cancer Res 14 2065 2074 1:CAS:528:DC%2BD1cXkt1aku74%3D 10.1158/1078-0432.CCR-07-4081 18381946 (Pubitemid 351551117)
9. Andre T, Tournigand C, Abbas F, et al (French Oncology Research Group) (2007). Anti-angiogenic treatment and colorectal cancer. Bull Cancer 94 Spec No: S211-S219.
10. T Shih C Lindley 2006 Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies Clin Ther 28 1779 1802 1:CAS:528: DC%2BD2sXhtVClsbg%3D 10.1016/j.clinthera.2006.11.015 17212999 (Pubitemid 46038527)
11. N Salesi G Bossone E Veltri, et al. 2005 Clinical experience with bevacizumab in colorectal cancer Anticancer Res 25 3619 3623 1:CAS:528:DC%2BD2MXps1Kgu74%3D 16101190
12. N Normanno A Morabito A De Luca, et al. 2009 Target-based therapies in breast cancer: current status and future perspectives Endocr Relat Cancer 16 3 675 702 1:CAS:528:DC%2BD1MXht1GnurvE 10.1677/ERC-08-0208 19525314
13. N Denduluri SX Yang AW Berman, et al. 2008 Circulating biomarkers of bevacizumab activity in patients with breast cancer Cancer Biol Ther 7 15 20 1:CAS:528:DC%2BD1cXms1OgsrY%3D 10.4161/cbt.7.1.5337 18059178
14. X Tao AK Sood MT Deavers, et al. 2009 Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulose cell tumours Gynecol Oncol 114 3 431 436 1:CAS:528:DC%2BD1MXptlSrt78%3D 10.1016/j.ygyno.2009.04.021 19524286
15. AA Garcia H Hirte G Fleming, et al. 2008 Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 76 82 1:CAS:528:DC%2BD1cXhsVCrsLc%3D 10.1200/JCO.2007.12.1939 18165643
16. EJ Abel CG Wood 2009 Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy Nat Rev Urol 6 7 375 383 1:CAS:528:DC%2BD1MXot12luro%3D 10.1038/nrurol.2009.102 19528960
17. A Rossi P Maione G Colantuoni, et al. 2009 Recent developments of targeted therapies in the treatment of non-small cell lung cancer Curr Drug Discov Technol 6 91 102 1:CAS:528:DC%2BD1MXotFKgt7o%3D 10.2174/ 157016309788488339 19519336
18. HK Seong JH Bae ES Kim, et al. 2009 Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short term effect Ophthalmologica 223 343 347 1:CAS:528:DC%2BD1MXhtVygurrJ 10.1159/000224782 19521133
19. MN Chilov JR Grigg TJ Playfair 2007 Bevacizumab (Avastin) for the treatment of neovascular glaucoma Clin Experiment Ophthalmol 35 494 496 10.1111/j.1442-9071.2007.01521.x 17651259 (Pubitemid 47162770)
20. T Kamba DM McDonald 2007 Mechanisms of adverse effects of anti-VEGF therapy for cancer Br J Cancer 96 1788 1795 1:CAS:528:DC%2BD2sXmtlyqur4%3D 10.1038/sj.bjc.6603813 17519900 (Pubitemid 46912024)
21. JJ Knightly D Agostino EE Cliffton 1962 The effect of fibrinolysin and heparin on the formation of peritoneal adhesions Surgery 52 250 1:STN:280:DyaF38%2FlvVKltg%3D%3D 14457251
22. H Konstantinidis A Slavakis K Ballas, et al. 2007 The effect of capecitabine on the healing of colonic anastomosis in rats Dis Colon Rectum 50 89 10.1007/s10350-006-0727-7 17115342
23. DH Alamdari M Ghayour-Mobarhan S Tavallaie, et al. 2008 Prooxidant-antioxidant balance as a new risk factor in patients with angiographically defined coronary artery disease Clin Biochem 41 375 380 1:CAS:528:DC%2BD1cXjs1SkurY%3D 10.1016/j.clinbiochem.2007.12.008 18191639
24. DH Alamdari K Paletas T Pegiou, et al. 2007 A novel assay for the evaluation of the prooxidant-antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients Clin Biochem 40 248 254 1:CAS:528:DC%2BD2sXntlOgtg%3D%3D 10.1016/j.clinbiochem.2006.10.017 17196578 (Pubitemid 46108709)
25. DH Alamdari E Kostidou K Paletas, et al. 2005 High sensitivity enzyme-linked immunosorbent assay (ELISA) method for measuring protein carbonyl in samples with low amounts of protein Free Radic Biol Med 39 1362 1367 1:CAS:528:DC%2BD2MXhtFKmt77O 10.1016/j.freeradbiomed.2005.06.023 16257645 (Pubitemid 41540091)
26. GK Reddy CS Enwemeka 1996 A simplified method for the analysis of hydroxyproline in biological tissues Clin Biochem 29 225 229 1:CAS:528:DyaK28XjsFWhu7k%3D 10.1016/0009-9120(96)00003-6 8740508 (Pubitemid 26142071)
27. DT Efron D Most HP Shi, et al. 2003 Modulation of growth factor and cytokine expression by nitric oxide during rat colon anastomotic healing J Gastrointest Surg 7 393 399 10.1016/S1091-255X(02)00433-X 12654565 (Pubitemid 36875778)
28. P Brasken M Lehto S Renvall 1990 Fibronectin, laminin, and collagen types I, III, IV and V in the healing rat colon anastomosis Ann Chir Gynaecol 79 65 71 1:STN:280:DyaK3czltFWjtA%3D%3D 1696798
29. P Brasken S Renvall M Sandberg 1991 Fibronectin and collagen gene expression in healing experimental colonic anastomoses Br J Surg 78 1048 1052 1:STN:280:DyaK38%2FjtlOnsA%3D%3D 10.1002/bjs.1800780908 1933184
30. DK Podolsky 1997 Healing the epithelium: solving the problem from two sides J Gastroenterol 32 122 126 1:STN:280:DyaK2s3htFeisg%3D%3D 10.1007/BF01213309 9058308 (Pubitemid 27075894)
31. MS Murphy 1998 Growth factors and the gastrointestinal tract Nutrition 14 771 774 1:CAS:528:DyaK1cXmslCisb8%3D 10.1016/S0899-9007(98)00081-1 9785359 (Pubitemid 28460276)
32. FJ Thornton A Barbul 1997 Healing in the gastrointestinal tract Surg Clin North Am 77 549 573 1:STN:280:DyaK2szjvVehsg%3D%3D 10.1016/S0039-6109(05)70568- 5 9194880 (Pubitemid 27256034)
33. TP Kingham HL Pachter 2009 Colonic anastomotic leak: risk factors, diagnosis and treatment Am Coll Surg 208 269 278 10.1016/j.jamcollsurg.2008.10. 015
34. FJ Guzman-de la Garza CR Camara-Lemarroy G Alarcon-Galvan, et al. 2009 Different patterns of intestinal response to injury after arterial, venous or arteriovenous occlusion in rats World J Gastroenterol 15 3901 3907 10.3748/wjg.15.3901 19701970
35. M Fedorova N Kuleva R Hoffmann 2009 Reversible and irreversible modifications of skeletal muscle proteins in a rat model of acute oxidative stress Biochim Biophys Acta 1792 12 1185 1193 1:CAS:528:DC%2BD1MXhsVKntrnF 19786098
36. JJ Lee E Chu 2007 An update on treatment advances for the first-line therapy of metastatic colorectal cancer Cancer J 13 276 281 1:CAS:528: DC%2BD2sXhtlertL%2FI 10.1097/PPO.0b013e3181570062 17921724
37. M Moehler MF Sprinzi M Abdelfattah, et al. 2009 Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients World J Gastroenterol 15 449 456 1:CAS:528:DC%2BD1MXisVSmt7s%3D 10.3748/wjg.15.449 19152449
38. CR Gordon Y Rojavin M Patel, et al. 2009 A review on bevacizumab and surgical wound healing. An important warning to all surgeons Ann Plast Surg 62 707 709 1:CAS:528:DC%2BD1MXmtFKmsrw%3D 10.1097/SAP.0b013e3181828141 19461291
39. FA Scappaticci L Fehrenbacher T Cartwright, et al. 2005 Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab J Clin Oncol 91 173 180 1:CAS:528:DC%2BD2MXhtVGltrnK
40. S Hapani D Chu S Wu 2009 Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta- analysis Lancet Oncol 10 559 568 1:CAS:528:DC%2BD1MXms12jtbk%3D 10.1016/S1470-2045(09)70112-3 19482548
41. HJ Raatschen Y Fu RC Brasch H Pietsch DM Shames BM Yeh 2009 In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model Invest Radiol 44 265 270 1:CAS:528:DC%2BD1MXntFyqtL0%3D 10.1097/RLI.0b013e31819f1b60 19346961
42. V Hsei GG DeGuzman A Nixon J Gaudreault 2002 Complexation of VEGF with bevacizumab decreases VEGF clearance in rats Pharm Res 19 1753 1756 1:CAS:528:DC%2BD38XotV2gs74%3D 10.1023/A:1020778001267 12458683 (Pubitemid 35305529)
43. T Mizobe Y Ogata H Murakami Y Akagi N Ishibashi S Mori T Sasatomi K Shirouzu 2008 Efficacy of the combined use of bevacizumab and irinotecan as postoperative adjuvant chemotherapy in colon carcinoma Oncol Rep 20 517 523 1:CAS:528:DC%2BD1cXht1ejt7nI 18695900
44. Igniatovic D, Aasland K, Pettersen M, Sund S, Chen Y, Spasojevic M, Nesgaard JM (2010). Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions. Am J Surg 200:270-275
45. K Blouhos MG Pramateftakis T Tsachalis D Kanellos T Zaraboukas G Koliakos D Betsis 2010 The integrity of colonic anastomoses following the intraperitoneal administration of oxaliplatin Int J Colorectal Dis 25 835 841 10.1007/s00384-010-0912-y 20217424
46. M Uludag K Ozdilli B Citgez G Yetkin OM Ipcioglu O Ozcan N Polat A Kartal P Torun A Isgor 2010 Covering the colon anastomoses with amniotic membrane prevents the negative effects of early intraperitoneal 5-FU administration on anastomotic healing Int J Colorectal Dis 25 223 232 10.1007/s00384-009-0833-9 19865820
47. Benjamin B, Hazut O, Shaashua L, Benish M, Zmora N, Barshack I, Hoffman A, Ben-Eliyahu S, Zmora O (2010). Effect of beta-blocker combined with COX-2 inhibitor on colonic anastomosis in rats. Int J Colorectal Dis. doi: 10.1007/s00384-010-0992-8